Research Progress on NLRP3 Inflammasome Mediating Inflammatory Response in Allergic Rhinitis through Pyroptosis

Corresponding author: Haiying Wu, wuhaiying1@kmmu.edu.cn

DOI: 10.12201/bmr.202510.00040

•  

  Abstract: 【Abstract】 The NLRP3 inflammasome is a multi-protein complex composed of NLRP3 protein, ASC, and Caspase-1, which can be activated by various stimuli and participates in the occurrence and development of allergic rhinitis by promoting the production of inflammatory factors and inducing pyroptosis. Studies have found that AR symptoms can be improved and inflammatory responses can be reduced by inhibiting the inflammasome or pyroptosis-related signaling pathways. The NLRP3 inflammasome is expected to become a new therapeutic target.

  Key words: Allergic rhinitis; NLRP3 inflammasome; Pyroptosis

  Submit time: 23 October 2025

  Copyright: The copyright holder for this preprint is the author/funder, who has granted biomedRxiv a license to display the preprint in perpetuity.
• html

• 图表

• Gao Lili. Research progress on targeting traditional Chinese medicine in the treatment of ischemic stroke based on the NLRP3 signaling pathway. 2025. doi: 10.12201/bmr.202509.00056

  QU Yiqian. Discussion on differentiation and treatment of six channels in Allergic Rhinitis based on pathways of wind-stroke and typhoid fever. 2025. doi: 10.12201/bmr.202503.00058

  Hui Danni, Han Mengjie, Li Erle, Xue Yajuan. Review on the immunotherapy in allergic rhinitis. 2024. doi: 10.12201/bmr.202410.00042

  zhangchaohui, yingyongjie, wangyilong, jinqiaozhi, chenwubin, taobaohong. . 2025. doi: 10.12201/bmr.202503.00009

  杨 欢, LIU Yue. Based on the theory of spleen as cardinal, the role of mitophagy mediating macrophage pyroptosis in atherosclerosis was discussed. 2025. doi: 10.12201/bmr.202508.00029

  LI Suping, HONG Suru, WU Xiayang. Based on network pharmacology and molecular docking technology to explore the molecular mechanism of Oulongma oral drops in the treatment of allergic rhinitis. 2025. doi: 10.12201/bmr.202508.00023

  . 2025. doi: 10.12201/bmr.202510.00031

  WANG XIAOQIONG. . 2024. doi: 10.12201/bmr.202409.00033

  Lin ZhiFeng, ZHANG ChuJian, LIU Dong, Kong YiJing. To explore the optimal intervention time of 1.25 (OH) 2D3 to protect renal interstitialfibrosis based on NF-κB inflammatory pathway. 2025. doi: 10.12201/bmr.202504.00063

  YANG Xiaodong. Research Progress of PHLDA3 in Diseases. 2024. doi: 10.12201/bmr.202407.00029

• ID	Submit time	Number	Download
  1	2025-10-02	10.12201/bmr.202510.00040V1	Download

• Public  Anonymous  To author only Submit Comments